Gilead Sciences Inc. has signed licensing deals with seven Indian generic drugmakers to manufacture its flagship chronic hepatitis C virus (HCV) medicine, Sovaldi (sofosbuvir), and an investigational ledipasvir/sofosbuvir combination for distribution in 91 developing countries. The deal will expand access to the medicines for as many an 100 million people living with HCV by steeply discounting the medicines' price tag.